JPWO2022223966A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022223966A5 JPWO2022223966A5 JP2023565152A JP2023565152A JPWO2022223966A5 JP WO2022223966 A5 JPWO2022223966 A5 JP WO2022223966A5 JP 2023565152 A JP2023565152 A JP 2023565152A JP 2023565152 A JP2023565152 A JP 2023565152A JP WO2022223966 A5 JPWO2022223966 A5 JP WO2022223966A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- domain
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 55
- 239000000427 antigen Substances 0.000 claims 51
- 102000036639 antigens Human genes 0.000 claims 51
- 108091007433 antigens Proteins 0.000 claims 51
- 239000003112 inhibitor Substances 0.000 claims 13
- 108010047303 von Willebrand Factor Proteins 0.000 claims 9
- 102100036537 von Willebrand factor Human genes 0.000 claims 9
- 229960001134 von willebrand factor Drugs 0.000 claims 9
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 6
- 206010002388 Angina unstable Diseases 0.000 claims 6
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 6
- 208000005189 Embolism Diseases 0.000 claims 6
- 208000035888 Immune-mediated thrombotic thrombocytopenic purpura Diseases 0.000 claims 6
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 208000004886 acquired thrombotic thrombocytopenic purpura Diseases 0.000 claims 6
- 206010000891 acute myocardial infarction Diseases 0.000 claims 6
- 238000004220 aggregation Methods 0.000 claims 6
- 230000002776 aggregation Effects 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 208000037803 restenosis Diseases 0.000 claims 6
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 3
- 206010003178 Arterial thrombosis Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000001528 Coronaviridae Infections Diseases 0.000 claims 3
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 3
- 208000033626 Renal failure acute Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 208000007718 Stable Angina Diseases 0.000 claims 3
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 3
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 3
- 208000007814 Unstable Angina Diseases 0.000 claims 3
- 208000035868 Vascular inflammations Diseases 0.000 claims 3
- 206010047249 Venous thrombosis Diseases 0.000 claims 3
- 201000011040 acute kidney failure Diseases 0.000 claims 3
- 208000012998 acute renal failure Diseases 0.000 claims 3
- 239000003146 anticoagulant agent Substances 0.000 claims 3
- 208000029078 coronary artery disease Diseases 0.000 claims 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 3
- 208000007475 hemolytic anemia Diseases 0.000 claims 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 201000011461 pre-eclampsia Diseases 0.000 claims 3
- 238000004393 prognosis Methods 0.000 claims 3
- 230000009424 thromboembolic effect Effects 0.000 claims 3
- 230000002537 thrombolytic effect Effects 0.000 claims 3
- 230000001732 thrombotic effect Effects 0.000 claims 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 102000002110 C2 domains Human genes 0.000 claims 1
- 108050009459 C2 domains Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229940126586 small molecule drug Drugs 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2105625.4A GB202105625D0 (en) | 2021-04-20 | 2021-04-20 | Von willebrand factor (VWF) inhibitors |
| GB2105625.4 | 2021-04-20 | ||
| PCT/GB2022/050989 WO2022223966A1 (en) | 2021-04-20 | 2022-04-20 | Von willebrand factor (vwf) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024514708A JP2024514708A (ja) | 2024-04-02 |
| JPWO2022223966A5 true JPWO2022223966A5 (https=) | 2025-03-26 |
| JP2024514708A5 JP2024514708A5 (https=) | 2025-03-26 |
Family
ID=76377797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565152A Pending JP2024514708A (ja) | 2021-04-20 | 2022-04-20 | フォンウィルブランド因子（ｖｗｆ）阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240228660A1 (https=) |
| EP (1) | EP4326778A1 (https=) |
| JP (1) | JP2024514708A (https=) |
| KR (1) | KR20240004332A (https=) |
| CN (1) | CN117597367A (https=) |
| AU (1) | AU2022262695A1 (https=) |
| BR (1) | BR112023021631A2 (https=) |
| CA (1) | CA3214716A1 (https=) |
| GB (1) | GB202105625D0 (https=) |
| IL (1) | IL307441A (https=) |
| MX (1) | MX2023012391A (https=) |
| WO (1) | WO2022223966A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202215432D0 (en) * | 2022-10-19 | 2022-11-30 | Ip2Ipo Innovations Ltd | Von Willebrand factor (VWF) antibody |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR070141A1 (es) * | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | Anticuerpos humanizados especificos para el factor von willebrand |
| EP2543678A1 (en) * | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
-
2021
- 2021-04-20 GB GBGB2105625.4A patent/GB202105625D0/en not_active Ceased
-
2022
- 2022-04-20 JP JP2023565152A patent/JP2024514708A/ja active Pending
- 2022-04-20 EP EP22720748.7A patent/EP4326778A1/en active Pending
- 2022-04-20 CA CA3214716A patent/CA3214716A1/en active Pending
- 2022-04-20 CN CN202280030093.5A patent/CN117597367A/zh active Pending
- 2022-04-20 AU AU2022262695A patent/AU2022262695A1/en active Pending
- 2022-04-20 BR BR112023021631A patent/BR112023021631A2/pt unknown
- 2022-04-20 US US18/556,638 patent/US20240228660A1/en active Pending
- 2022-04-20 IL IL307441A patent/IL307441A/en unknown
- 2022-04-20 KR KR1020237036079A patent/KR20240004332A/ko active Pending
- 2022-04-20 WO PCT/GB2022/050989 patent/WO2022223966A1/en not_active Ceased
- 2022-04-20 MX MX2023012391A patent/MX2023012391A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022046656A (ja) | 抗凝固因子ｘｉ抗体 | |
| EP2525812B1 (en) | Anticoagulant antidotes | |
| AU2011208719B2 (en) | Anticoagulant antidotes | |
| CA2869477C (en) | Humanized and chimeric anti-factor c3 antibodies and uses thereof | |
| JP7028471B2 (ja) | 第ｘｉ因子の活性部位に対するモノクローナル抗体及びその使用 | |
| CN113474374B (zh) | 抗FXI/FXIa抗体及其用途 | |
| NO348522B1 (no) | Bispesifikke antistoffer som substituerer for funksjon av blodkoagulasjonsfaktor VIII, sammensetning inneholdende slike og anvendelse, samt kit omfattende et bispesifikt antistoff. | |
| JP6033459B2 (ja) | Ｂｍｐ−６抗体 | |
| CN113717285B (zh) | 抗人d-二聚体抗体及其应用 | |
| EP3412688A1 (en) | Thrombin antibody, antigen-binding fragment and pharmaceutical use thereof | |
| US20230340088A1 (en) | Fungal (1,3)-Beta-D glucan-directed monoclonal antibody, coding genes thereof, expression thereof and application thereof | |
| JPWO2022223966A5 (https=) | ||
| CN114594272B (zh) | 用于检测β-淀粉样蛋白的产品和方法 | |
| RU2749591C1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, СПЕЦИФИЧНО СВЯЗЫВАЮЩЕЕСЯ С N-КОНЦОМ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ, В КАЧЕСТВЕ ЭФФЕКТИВНОГО ИНГРЕДИЕНТА ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОБУСЛОВЛЕННОГО МИГРАЦИЕЙ КЛЕТОК | |
| WO1997023509A1 (fr) | ANTICORPS MONOCLONAL, ANTI COMPLEXE 'Xa . TFPI' ET SON UTILISATION | |
| TW201922797A (zh) | 凝血酶抗體、其抗原結合片段及醫藥用途 | |
| JPWO2019246176A5 (https=) | ||
| CN120468435A (zh) | 一种检测阿尔茨海默病的抗体试剂盒及其应用 | |
| WO2025172467A1 (en) | Endotrophin assay | |
| KR20250158059A (ko) | 인간 보체 성분 2 결합 분자 | |
| CN120870574A (zh) | 一种检测hmgb1的试剂盒与检测方法 | |
| CN121108332A (zh) | 一种抗tat单克隆抗体及其编码序列和应用 | |
| JPWO2024017331A5 (https=) | ||
| RU2025110616A (ru) | CD163 Связывающий белок | |
| HK40069564B (zh) | 抗fxi/fxia抗体、其抗原结合片段及医药用途 |